Long-term outcomes of patients with Crohn’s disease who received infliximab or adalimumab as the first-line biologics.

Long-term outcomes of patients with Crohn’s disease who received infliximab or adalimumab as the first-line biologics. J Gastroenterol Hepatol. 2019 Feb 06;: Authors: Inokuchi T, Takahashi S, Hiraoka S, Toyokawa T, Takagi S, Takemoto K, Miyaike J, Fujimoto T, Higashi R, Morito Y, Nawa T, Suzuki S, Nishimura M, Inoue M, Kato J, Okada H Abstract BACKGROUND AND AIM: Although previous studies compared the efficacy of infliximab (IFX) versus adalimumab (ADA) as the first-line biologics for Crohn’s disease (CD), the difference in long-term prognosis based on which biologic was used…

Read More

Regional Variations in the Use of Biologics and Immunomodulators among Korean Patients with Inflammatory Bowel Diseases.

Regional Variations in the Use of Biologics and Immunomodulators among Korean Patients with Inflammatory Bowel Diseases. J Gastroenterol Hepatol. 2019 Jan 23;: Authors: Han M, Jung YS, Cheon JH, Park S Abstract BACKGROUND: Variation in medical care can be an obstacle to improving quality and outcome of treatment. We conducted a nationwide, population-based study to identify regional variations in medication prescription rates in Korean patients with inflammatory bowel diseases (IBD). METHODS: Using the National Health Insurance claims, we collected data on patients diagnosed with IBD (8,974 cases of Crohn’s disease…

Read More

Immunogenicity is not the driving force of treatment failure in vedolizumab-treated inflammatory bowel disease patients.

Immunogenicity is not the driving force of treatment failure in vedolizumab-treated inflammatory bowel disease patients. J Gastroenterol Hepatol. 2018 Dec 27;: Authors: Van den Berghe N, Verstockt B, Tops S, Ferrante M, Vermeire S, Gils A Abstract BACKGROUND AND AIM: The pivotal GEMINI trials reported low immunogenicity of vedolizumab. However, anti-vedolizumab antibodies (AVA) are frequently underestimated since most assays are not drug-tolerant and unable to detect anti-drug antibodies while there is drug in the circulation. This study aimed to explore which anti-drug antibody assay is best suited to detect AVA…

Read More

Compound polysaccharides ameliorate experimental colitis by modulating gut microbiota composition and function.

Compound polysaccharides ameliorate experimental colitis by modulating gut microbiota composition and function. J Gastroenterol Hepatol. 2018 Dec 27;: Authors: Cai Y, Liu W, Lin Y, Zhang S, Zou B, Xiao D, Lin L, Zhong Y, Zheng H, Liao Q, Xie Z Abstract BACKGROUND AND AIM: Inflammatory bowel disease (IBD) results from a dysregulated immune response to intestinal microbial flora in individuals with genetic predisposition(s). This study aimed to determine the effects of compound polysaccharides (CP) containing yam polysaccharide and inulin on the rat model of colitis induced by 2,4,6-trinitrobenzenesulfonic acid…

Read More

Incidence and clinical impact of perianal disease in patients with ulcerative colitis: A nationwide population-based study.

Related Articles Incidence and clinical impact of perianal disease in patients with ulcerative colitis: A nationwide population-based study. J Gastroenterol Hepatol. 2018 Nov 22;: Authors: Song EM, Lee HS, Kim YJ, Oh EH, Ham NS, Kim J, Hwang SW, Park SH, Yang DH, Ye BD, Byeon JS, Myung SJ, Yang SK Abstract BACKGROUND AND AIM: The risk and clinical impact of perianal disease (PAD) in ulcerative colitis (UC) patients have not been fully evaluated. We investigated the incidence of PAD in UC patients and compared clinical characteristics and outcomes of…

Read More

Predictors of mucosal healing during induction therapy in patients with acute moderate-to-severe ulcerative colitis.

Related Articles Predictors of mucosal healing during induction therapy in patients with acute moderate-to-severe ulcerative colitis. J Gastroenterol Hepatol. 2018 Dec 14;: Authors: Motobayashi M, Matsuoka K, Takenaka K, Fujii T, Nagahori M, Ohtsuka K, Iwamoto F, Tsuchiya K, Negi M, Eishi Y, Watanabe M Abstract BACKGROUND AND AIM: The treat-to-target strategy has emerged in ulcerative colitis management. Mucosal healing is the best target, albeit not in induction therapy of acute diseases as clinical conditions vary over a short duration. To determine the targets during induction therapy for acute ulcerative…

Read More

Disease course of inflammatory bowel disease unclassified in a European population-based inception cohort – an Epi-IBD study.

Related Articles Disease course of inflammatory bowel disease unclassified in a European population-based inception cohort – an Epi-IBD study. J Gastroenterol Hepatol. 2018 Dec 18;: Authors: Burisch J, Chetcuti Zammit S, Ellul P, Turcan S, Duricova D, Bortlik M, Winther Andersen K, Andersen V, Kaimakliotis IP, Fumery M, Gower-Rousseau C, Girardin G, Valpiani D, Goldis A, Brinar M, Čuković-Čavka S, Oksanen P, Collin P, Barros L, Magro F, Misra R, Arebi N, Eriksson C, Halfvarson J, Kievit HAL, Pedersen N, Kjeldsen J, Myers S, Sebastian S, Katsanos KH, Christodoulou DK,…

Read More

Emerging trends of inflammatory bowel disease in South Korea: a nationwide population-based study.

Related Articles Emerging trends of inflammatory bowel disease in South Korea: a nationwide population-based study. J Gastroenterol Hepatol. 2018 Nov 16;: Authors: Kwak MS, Cha JM, Lee HH, Choi YS, Seo SI, Ko KJ, Park DI, Kim SH, Kim TJ Abstract Background and Aims Little is known regarding the exact burden of inflammatory bowel disease (IBD) in Asian countries because previous epidemiologic studies were hospital-based. We aimed to develop and validate an operational definition of IBD cases from health insurance claims data and to examine the epidemiological features of IBD…

Read More

Ginsenoside Rb1 promotes intestinal epithelial wound healing through ERK and Rho signaling.

Ginsenoside Rb1 promotes intestinal epithelial wound healing through ERK and Rho signaling. J Gastroenterol Hepatol. 2018 Nov 05;: Authors: Toyokawa Y, Takagi T, Uchiyama K, Mizushima K, Inoue K, Ushiroda C, Kashiwagi S, Nakano T, Hotta Y, Tanaka M, Dohi O, Okayama T, Yoshida N, Katada K, Kamada K, Ishikawa T, Handa O, Konishi H, Naito Y, Itoh Y Abstract BACKGROUND AND AIM: Daikenchuto, a traditional Japanese herbal medicine, has been reported to exhibit anti-inflammatory effects against intestinal inflammation. However, whether daikenchuto has a therapeutic effect against intestinal mucosal injuries…

Read More
<< Go Back